Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria

Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fracti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical medicine 2020-07, Vol.9 (7), p.2089
Hauptverfasser:	Camps-Vilaró, Anna, Delgado-Jiménez, Juan F, Farré, Núria, Tizón-Marcos, Helena, Álvarez-García, Jesús, Cinca, Juan, Dégano, Irene R, Marrugat, Jaume
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Clinical medicine Diabetes Ejection fraction Heart failure Internal medicine Medical prognosis Mortality Patients Physicians Primary care
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!